Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Commissioner Tries To Allay Concerns About Inspection Postponements

Executive Summary

Screenings at ports of entry may be modified, but the drug supply remains safe and secure, Stephen Hahn tells House Committee, arguing that other tools will allow for continued facility policing during the coronavirus outbreak even if the absence of inspections.

You may also be interested in...



US FDA Would Get Funding Boost Under House Coronavirus Stimulus Bill

Agency appears to have a fair bit of flexibility in how to spend the additional $80m slated for coronavirus activities.

More FDA Funding In House Coronavirus Stimulus Bill, But No OTC Purchases With Pre-tax Savings

An additional $160m is allocated to FDA in House coronavirus-related stimulus bill aimed at fighting the pandemic and helping the wobbling economy. It would not, as a similar Senate bill proposes, once again allow using pre-tax savings accounts to buy OTC drugs.

‘Big Shoes To Fill’: US FDA Commissioner Hahn’s Baptism By Fire

Every new FDA commissioner faces a challenge earning credibility with Congress and the public, but in the context of COVID-19, Stephen Hahn has a double challenge of a public health crisis – and the ongoing prominence of his predecessor at the agency.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS141829

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel